Orange Book Listings Under Scrutiny: What’s In, What’s Out, and Why It Matters

March 2025

Abstract

The Food and Drug Administration’s (FDA) Orange Book, officially titled Approved Drug Products with Therapeutic Equivalence Evaluations, plays a key role in the U.S. pharmaceutical patent and exclusivity system. The Hatch-Waxman Act requires innovative drug companies to list certain patents covering their FDA-approved products in the Orange Book, and requires generic drug companies to certify how their drugs relate to those listed patents when seeking regulatory approval. A critical feature of this system is that, under certain circumstances, the listing of a patent in the Orange Book can lead to an automatic 30-month stay of FDA approval for the generic drug. This statutorily-mandated delay in generic approval provides significant market protection for innovator companies that would otherwise be irreparably harmed by generic entry prior to expiration of properly-listed patents.

Subscribe to reador

Few statutory provisions have generated as much controversy in the pharmaceutical space as the federal government’s retained authority to override patent rights in the public interest. While patent exclusivity is...Read more

Joanna Brougher

Owner & Principal, BioPharma Law Group PLLC, USA

March-In Rights at a Crossroad: What Biopharma Needs To Know Under Trump Administration

Few pieces of legislation have shaped the modern innovation landscape as profoundly as the Bayh-Dole Act of 1980. By allowing universities, small businesses, and non-profit organizations to retain ownership...Read more

Joanna Brougher

Owner & Principal, BioPharma Law Group PLLC, USA

Ways to Avoid Having your Patents Cellected*

The Court of Appeals for the Federal Circuit caused frustrations when it decided to affirm the U.S. Patent Office’s findings that claims in four patents were unpatentable because they are...Read more

Orange Book Listings Under Scrutiny: What’s In, What’s Out, and Why It Matters

Abstract

Related Papers